Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
For children with IgA nephropathy (IgAN), achieving sustained proteinuria remission early on could be a game-changer. A new study found that kids who hit complete, sustained remission (CSR) for more than 90 days had significantly better kidney function at both 4 and 5 years post-biopsy. Even a brief 3-month remission offered meaningful long-term protection.
For children with IgA nephropathy (IgAN), getting proteinuria under control early isn't just a short-term win — it pays dividends years down the line. A new study published in Nephrology Dialysis Transplantation analyzed 709 children with biopsy-confirmed IgAN across a multiethnic cohort and found that those who achieved complete, sustained proteinuria remission (CSR) lasting more than 90 days had significantly better kidney function at 4 and 5 years compared to those who didn't. Notably, even remission lasting just 3 months conferred meaningful long-term protection against eGFR decline.
The study also shed light on what drives remission. RAS inhibitors boosted the likelihood of achieving CSR by 62%, while younger age, higher baseline eGFR, and the absence of segmental sclerosis were independently associated with better outcomes. Interestingly, nearly 30% of children achieved CSR without any pharmacological treatment.
Key Takeaways:
Why it matters: IgAN affects up to one-third of children undergoing kidney biopsies, and up to 20% progress to serious kidney disease. Identifying CSR as an early, measurable predictor of long-term outcomes gives clinicians a practical tool to assess prognosis and guide treatment decisions — potentially before irreversible damage sets in.
